Though PD-L1 expression and MSI-H are established biomarkers for predicting response to ICIs in CRC [8, 9], the response rate to ICIs among CRC patients with high PD-L1 expression or MSI-H is variable. This evidence concerns the gene CD274 and colorectal carcinoma.